Almirall Leaves Losses Behind and Earns 11 Million Up to September

Almirall leaves the red numbers behind. The Spanish pharmaceutical company, which is up 2% on the stock market in Thursday’s morning session, posted a net profit of €10.9 million from January to September 2022, compared with a loss of €39.4 million in the same period of 2021, according to the results sent by the company to the Spanish Securities and Exchange Commission (Cnmv).

The improvement in Almirall’s results is due to the fact that it has not had extraordinary impacts as in 2021, when it recorded an asset impairment of more than €100 million. On the other hand, the company has increased its revenues thanks to the good performance of new products.

Almirall’s net sales stood at €633.8 million in the cumulative January-September 2022, which translates into an increase of 5.3% compared to the same period of the previous year. The company attributes this upturn to the strong contribution of sales from the dermatology portfolio in the European market.

Read more about Almirall and get comprehensive access to global crowdfunding business, stock market, finance news, and trending topics with the Born2Invest companion app. Born2Invest mobile app makes it easy for you to keep informed, to intuitively move from story to story, and from section to section. Our clean design lets you read articles without clutter, and use the app with no limits on how many articles you can view.

Almirall achieved sales of €634 million from January to September

Gross operating profit (Ebitda), however, fell by 19.2% year-on-year to €146.4 million, in line with the Catalan drugmaker’s expected performance, as 2021 saw product divestments and deferred revenues.

Investment in research and development (R&D) increased by 11.3% in the period, to €71.6 million euros. Almirall expects R&D expenses to reach around 12% of net sales for the full year, due to investment in Phase 3b studies focused on Lebrikizumab, studies for the treatment of Klisyri, as well as increased spending on earlier-stage assets, such as Anti IL1-Rap and IL-2 mutant fusion protein.

General and administrative expenses were €308.9 million, up 6.3% from last year, as Almirall continues to invest in its newly launched products, such as Wynzora, and Klisyri in the US and Europe, and the rollout of Ilumetri, the latter being a treatment for psoriasis.

Following these results, Almirall has confirmed its financial estimates for 2022. “We are pleased with the good business momentum we have seen in the third quarter, showing strong growths; our core business continues to perform well, in line with our expectations, which puts us on target to achieve our financial estimates for 2022,” highlighted Almirall’s chairman and interim CEO, Carlos Gallardo.

__

(Featured image by geralt via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.